Introduction
Infection with Kaposi's sarcoma (KS)-associated herpesvirus (KSHV) or Human herpesvirus type 8 (HHV-8) 1 is linked to all forms of KS, as well as to primary effusion lymphoma (PEL), [2] [3] [4] to some forms of multicentric Castelman's disease 5, 6 as well as to other solid lymphomas. [7] [8] [9] KSHV is a g-2 herpesvirus that infects multiple cell types. Infection of circulating mononuclear cells, particularly B cells, provides a reservoir for latent virus and participates in the viral dissemination. Infection of endothelial cells of lymphatic origin leads to the development of KS. PEL or body cavity-based lymphoma is a high-grade B-cell malignancy that belongs to the group of non-Hodgkin's B-cell lymphomas (NHL). PEL is characterized by pleural, pericardial or peritoneal lymphomatous effusions in the absence of a solid tumor mass. 10, 11 That KSHV targets both endothelial cells and B lymphocytes and suggests a possible interaction between PEL cells and endothelial cells.
Angiogenesis, the formation of new blood vessels from existing ones, is a prerequisite for the growth and metastasis of many solid tumors. [12] [13] [14] Angiogenesis is predominantly mediated by vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (b-FGF) 15, 16 secreted by either tumor and/or stromal cells. A role of angiogenesis in the physiopathology of hematological malignancies has been demonstrated. The most compelling evidence is in multiple myeloma (MM) where a correlation between the extent of bone marrow angiogenesis and both plasma cell proliferative index and disease progression has been described. 17, 18 More significantly, the antiangiogenic drug thalidomide resulted in a high response rate in MM patients resistant to chemotherapy. 19 Similarly, in NHL, a correlation between the degree of angiogenesis and the stage of the lymphoma was reported 20 as well as a direct correlation between the pretreatment level of angiogenic factors and prognosis. 21, 22 In leukemia, increased angiogenesis in the bone marrow and increased level of proangiogenic factors were demonstrated in children with acute lymphoblastic leukemia 23 and in adults with acute and chronic myeloid leukemia, myelodysplastic syndromes [24] [25] [26] or chronic lymphocytic leukemia. [27] [28] [29] It was shown that KSHV-infected cells secrete VEGF and induce in vitro angiogenesis. 30 Recent studies reported that b-integrins 31 or induction of angiopoietin-2 32 mediates PEL-induced tube formation. Cells influence their immediate microenvironment either through paracrine mechanisms or through direct cell-cell interaction, such as adhesion and gap junction-mediated communication. Gap junctions represent an efficient and specific conduit to deliver small size molecules that are characteristically membrane impermeable, produced in low concentration or have a short half-life. This includes cell metabolites and second messengers such as cyclic nucleotides, inositol trisphosphate and calcium. 33 These gap junctions are clusters of transmembranous aqueous channels composed of structurally related proteins known as connexins (Cx), 34 which play an important role in tissue organization and cellular differentiation. [35] [36] [37] There are evidences for the existence of functional gap junctions in endothelial cells 38, 39 and normal lymphocytes. 40, 41 However, although the endothelium interacts with many cell types including leukocytes, [42] [43] [44] astrocytes, 45 smooth muscle cells 46 and cancer cells, 47, 48 communication of neoplastic lymphocytes with the endothelium has only been reported for human T-lymphotropic virus type 1 (HTLV-1)-infected adult T-cell leukemia/lymphoma cells. 49 In this study, we show that VEGF and VEGF receptors mediate in vitro angiogenesis induced by PEL cells. Using a PEL animal model, we show significantly higher levels of VEGF and b-FGF proteins in the ascitic fluid when compared to in vitro cell line supernatants. We demonstrate that extravasation of PEL cells through the endothelial cells' monolayer is partially mediated by VEGF and VEGF receptors. Finally, we show that PEL cells express Cx and establish functional gap junctions with endothelial cells. These results represent the second evidence for a heterocellular communication in a hematological malignancy.
Materials and methods

Cells, reagents and antibodies
BC-3 and body-cavity-based lymphoma (BCBL-1) cell lines are KSHV þ /EBV À malignant B cells derived from PEL patients 50, 51 and were obtained from American Type Culture Collection (Manassas, VA, USA). HTLV-1-transformed HuT-102 cells were used as a positive control. HTLV-1 negative CD4 þ T cell line contagious equine metritis (CEM) was used as a negative control. Cells were grown in RPMI-1640 medium containing 10% heat inactivated fetal calf serum and antibiotics. Cell concentration of 4 Â 10 5 cells per ml was chosen for seeding in all experiments. Human aortic endothelial cells (HAECs) (Clonetics, Maryland, USA) were grown in endothelial growth medium supplemented with human epidermal growth factor (0.1%), hydrocortisone (0.1%), gentamycine sulfate (0.1%), bovine brain extract (0.4%) and fetal bovine serum (2%) at an initial cell concentration of 4 Â 10 5 per ml. PTK-787/ZK-222584 (PTK/ZK), a selective inhibitor of the tyrosine kinase activity of the VEGF receptors (VEGFR-1, VEGFR-2, VEGFR-3), was obtained from Novartis (Basel, Switzerland). Anti-VEGF monoclonal antibody bevacizumab (Avastin) was obtained from Hoffmann La Roche (Basel, Switzerland). Rabbit polyclonal antibodies to Cx43 and its blocking peptide were purchased from Zymed (San Francisco, CA, USA). Rabbit anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Biogenesis, Stinford Fload, UK) antibodies were used to assess protein loading.
Mouse model of PEL
NOD.CB17-Prkdc SCID /J (NOD/SCID) mice were purchased from Charles River (Paris, France). Mice were injected intraperitoneally with 2 Â 10 6 BC-3 and BCBL-1 PEL cell lines as previously described. 52 Tumors that developed in these mice presented as a malignant ascitis frequently accompanied by significant abdominal distension, and these observations are consistent with the clinical manifestations of PEL in humans, which include pericardial and/or peritoneal effusions and abdominal distension. 52 This study was approved by the Institutional Animal Care and Utilization Committee of the American University of Beirut.
RNA isolation and reverse transcription-PCR
cDNA was synthesized from 100 or 500 ng of total cellular RNA, isolated by Trizol-reagent (Gibco-BRL, Paisley, UK), using reverse transcriptase (Super script II, Gibco-BRL). The cDNA was then amplified by PCR using Taq DNA polymerase (Gibco-BRL). We used PCR primers that recognize all VEGF and b-FGF isoforms, Cx43-and Cx45-specific primers and b-actin specific primers, as described. 49 The PCR conditions consisted of a precycle of 95 1C for 3 min followed by 35 cycles consisting of 95 1C for 1 min; 55 1C for 1 min and 72 1C for 1 min. Afterward, a final extension at 72 1C for 7 min was performed. The primers sequences are presented in Table 1 . Amplification of the housekeeping gene, b-actin, was used to assess RNA quality. PCR amplified products were separated by electrophoresis in 1.5% agarose gel and visualized with ethidium bromide staining.
Western blot analysis
Approximately 4 Â 10 6 cells were solubilized at 4 1C in lysis buffer consisting of 125 mM Tris-HCl (pH 6.8), 2% sodium dodecyl sulfate (SDS), 2.5% b-mercaptoethanol and 10% glycerol. Protein concentration was determined by the BioRad DC protein assay and 50 mg of proteins was loaded onto a 12% SDS-polyacrylamide gel, subjected to electrophoresis and transferred onto nitrocellulose membranes. After blocking of the membrane in 5% skimmed milk in Tris-buffered saline containing 0.05% Tween-20, the blots were incubated with specific antibodies. The blots were washed and protein bands were visualized using chemiluminescence (Amersham, Buckinghamshire, UK).
Enzyme-linked immunosorbent assay
Cells were seeded at a concentration of 0.2 Â 10 6 cells per ml. Levels of soluble VEGF and b-FGF proteins were measured by enzyme-linked immunosorbent assay (ELISA) (DVE00, R&D Systems Minneapolis, MN, USA) as recommended by the manufacturer, in the cell-free supernatant harvested after 72 h of culture, or in the ascitic fluid harvested from NOD/SCID PEL mice. All experiments were performed in triplicate.
Matrigel-induced capillary tube formation
The Matrigel assay has been widely used as an in vitro measure of angiogenesis and was performed as described previously. 53 Briefly, 12-well plates were coated with 200 ml per well growth factor-reduced Matrigel (Becton Dickinson, San Jose, CA, USA) and allowed to stand for 30 min at 37 1C to form a gel layer. HAECs (0.4 Â 10 5 cells) were cultured for 18 h then incubated at Table 1 Primer sequences
Abbreviations: b-FGF, basic fibroblast growth factor; Cx, connexin; VEGF, vascular endothelial growth factor. 
Invasion assay
Six-well tissue-culture plates were fitted with inserts (8 mm pore size) that have been coated with growth factor-reduced EHS (Matrigel 125 ng cm using a cotton swab. The membrane of the insert was then removed and mounted on a microscopic slide and examined by fluorescence microscopy. Fluorescent tumor cells that successfully invaded through the endothelial layer were photographed and counted.
Results
PEL cells induce angiogenic factors secretion in vitro and in vivo
We first investigated the level of VEGF and b-FGF expression, the two major angiogenic factors, both at the mRNA and the protein levels. As previously reported, both KSHV-transformed PEL cells (BC-3 and BCBL-1) 30 and HTLV-1-transformed ATLderived cells (HuT-102) 49 express the three VEGF mRNA transcripts, while the T-cell-negative controls (CEM) express only the 518 bp transcript (Figure 1a The levels of secreted VEGF and b-FGF were determined by ELISA in the cell-free culture supernatant. As previously reported, 30 PEL cells produced variable levels of VEGF ranging from 680 pg ml À1 in the BC-3 cell line to 730 pg ml À1 in the BCBL-1 cell line (Figure 1b) . HuT-102 cells produced 1400 pg ml À1 VEGF whereas CEM control cells were below the assay detection level (10 pg ml À1 ). Surprisingly, levels exceeding 5000 pg ml À1 were detected in the ascitic fluid from the NOD/SCID PEL mice (BC-3F and BCBL-1F cells, Figure 1b) . In sharp contrast, and despite the fact that these cell lines produce b-FGF transcripts and b-FGF proteins, the amount of secreted b-FGF into the culture medium of BC-3 and BCBL-1 Figure 2 Primary effusion lymphoma (PEL) cell-induced endothelial tube formation in vitro is vascular endothelial growth factor (VEGF) dependent. Human aortic endothelial cells (HAECs) were plated on growth factor-reduced Matrigel in the presence of culture medium, BC-3, body-cavity-based lymphoma (BCBL-1), HuT-102 and contagious equine metritis (CEM) cell-free supernatant with or without PTK/ZK or anti-VEGF antibodies (bevacizumab (BEV)). Plates were photographed using fluorescence microscopy (magnification Â 20) after Hoechst nuclear staining. (Figure 1c) . As reported, 49 HuT-102 cells secreted b-FGF 12 pg ml À1 , while the level of b-FGF secreted by CEM cells was below the limit of detection (Figure 1c ). Again, a dramatic secretion of b-FGF (4800 pg ml À1 ) was observed in the ascitic fluid from the NOD/SCID PEL mice (BC-3F and BCBL-1F cells in Figure 1c ). Altogether, these results indicate either that these angiogenic factors are produced by another cell type in vivo following interaction with PEL cells, or that their secretion by PEL cells gets activated in vivo and suppressed or altered in vitro. Overall, the demonstration that PEL cells induce accumulation of tremendous levels of VEGF and b-FGF in vivo suggests that angiogenesis might play an important role in PEL pathogenesis.
Angiogenesis and gap junctions in PEL
L Haddad et al cells were below the assay detection level
PEL cells induce endothelial cell tube formation is VEGF-dependent
The functional consequence of PEL-induced angiogenic factor secretion on endothelial cells was then evaluated. HAECs were plated onto growth factor-reduced Matrigel and incubated with PEL (BC-3, BCBL-1) cell-free supernatant for 48 h. When cultured alone HAECs do not form a structured network. On the contrary, the addition of HuT-102, BC-3 or BCBL-1 cell supernatants (Figure 2) to HAECs induced the formation a network of capillary-like tubules with multicentric junctions. As a control, adding CEM supernatant did not induce the formation of such structures ( Figure 2 ). As expected, the addition of a tyrosine kinase inhibitor of VEGF receptors (PTK/ZK) or of an anti-VEGF antibody (bevacizumab (BEV)) (Figure 2 
PEL cells adhere to and communicate with endothelial cells through gap junctions
Co-culture of HAEC with calcein-labeled BC-3 or BCBL-1 cells resulted in a progressive transfer of fluorescence from the lymphoma cells to the HAEC (Figure 3a) . As early as 15 min, PEL cells adhered to the endothelial cell monolayer resulting in an increase in mean fluorescence intensity (MFI) of HAEC.
Increasing the ratio of BC-3 and BCBL-1 cells to HAEC resulted in a progressive increase in dye transfer (Figure 3b, lanes 2-4) . Statistical comparison by one-way analysis of variance Dunnet's test of the MFI of HAEC between HAEC as a control and HAEC þ BC-3 at cell-to-cell ratios of 1:0.5, 1:1 and 1:2 revealed a highly statistically significant increase of MFI of HAEC with P-values of o0.01, o0.001 and o0.0001, respectively. This reflects dye transfer through gap junctions from the PEL cells. As a control, the addition of a gap junction inhibitor 18-a-glycyrrhetinic acid (18aGA) resulted in a decreased endothelial cell fluorescence (Figure 3b , lane 5). Consistent with these results, RT-PCR analysis using specific primers of the gap junction proteins, Cx, showed that both cell lines expressed mRNA for Cx43 whereas Cx45 was predominantly expressed in BCBL-1 cells (Figure 3c) . Western blot analysis further demonstrated that both PEL cell lines express a basal level of Cx43 protein (Figure 3d) . As a control GAPDH western blot demonstrates the equal amount of protein loaded in each lane.
PEL cells invade through endothelial cells using a VEGF-dependent mechanism
The ability of PEL cells to go through the endothelial cell barrier was assessed using an invasion assay that utilizes a twocompartment model. (Figure 4a) ). Addition of function blocking anti-VEGF antibody (BEV), or a tyrosine kinase inhibitor of VEGF receptors (PTK/ZK), reduced the number of BC-3 cells invasion to 77% (P ¼ 0.13, Dunnet's test) and 72% (P ¼ 0.07, Dunnet's test) of untreated BC-3 cells, respectively, after 24 h. Similarly, BEV or PTK/ZK reduced the number of BCBL-1 invasion to 59% (P ¼ 0.05, Dunnet's test) and 64% (P ¼ 0.03, Dunnet's test) of untreated BCBL-1 cells, respectively, after 24 h (Figure 4b) . Importantly, addition of the gap junction inhibitor 18aGA reduced the number of BC-3 cells invasion to 38% (P ¼ 0.01, Dunnet's test). These data highlight the critical role of VEGF and gap junction-mediated heterocellular communication in the invasive potential of PEL-derived cells.
Discussion
Angiogenesis is critical for the growth of solid tumors 12, 13 and of some hematological malignancies. 17, 28, 54, 55 Our findings that in vitro angiogenesis induced by PEL cells is blocked by anti-VEGF antibodies or by VEGF receptors inhibitor, and the significantly higher in vivo levels of VEGF and b-FGF proteins in the ascitic fluid of NOD/SCID PEL mice as compared to in vitro cultured cell lines, strongly support a potential role for VEGF and b-FGF in KSHV-associated diseases.
However, the pathways leading to the angiogenic factors secretion by PEL cells and thus angiogenesis remain complex. Previous studies showed that different players of the KSHV could be responsible of the VEGF induction and its potential angiogenic effect. Aoki et al. 56 suggested that vIL6 promote angiogenesis in an autocrine mechanism indirectly by inducing VEGF expression. Liu et al. 57 provided further evidence that VEGF is a critical mediator of angiogenesis stimulation by vIL-6 in vitro and in vivo. Hamden et al. 58 showed that Raf regulates the expression of a variety of growth factors including VEGF. On the other hand, Wang et al. 59 demonstrated that K1, the transmembrane glycoprotein that is encoded by the first open reading frame of KSHV, is responsible of the VEGF upregulation mediated at the transcriptional level by VEGF promoter activation. Interestingly, we show impressive levels of VEGF and b-FGF in the ascitic fluid of PEL NOD/SCID mice. This might indicate either that these angiogenic factors are produced by another cell type in vivo following interaction with PEL cells, or that VEGF and b-FGF secretion by PEL cells gets activated in vivo by the growing environment and by the contribution of other cytokines or signaling pathways.
We also demonstrate a direct cell-cell communication through gap junctions. Gap-junctional coupling of tumor cells facilitates their invasion of normal tissue. 60 We have previously demonstrated the role of gap junctions in heterocellular communication between blood cancer cells and endothelium of the target organ of metastasis. 47 We have also previously reported the first evidence for gap junction-mediated heterocellular communication between endothelial cells and hematological malignant cells: HTLV-1-infected adult T-cell leukemia/ lymphoma cells. Here, we show the second example of gap junction-mediated heterocellular communication between endothelial cells and a hematological malignancy secondary to viral infection. Interestingly, angiogenic factors upregulate endothelial cells' ability to communicate through gap junctions and therefore greatly enhance the significance of heterocellular communications with tumor cells. 61, 39 Although the gap junction protein Cx43 is expressed in both PEL-derived cells and control T cells (CEM), gap junction-mediated heterocellular communication requires specific adhesion to endothelial cells, which is significantly more important for PEL cells (data not shown).
Finally, the invasion of the PEL-derived cells through the endothelium further confirms the importance of direct cell-cell interaction in the extravasation process of the tumor cells. The data shown here highlight the role of VEGF and its receptor, and of gap junction-mediated heterocellular communication, partially mediating this invasion. Indeed, we were able to show the invasion of the PEL-derived cells through the endothelial barrier and its partial inhibition by a VEGFR inhibitor, by an anti-VEGF antibody and by the gap junction inhibitor. However, complete inhibition of PEL-derived cell extravasation through the endothelial barrier may require the blockage of all the invasion mediators such as metalloproteinases (MMP) which were shown to play a major role in the migration process of the tumor cells by the degradation of the endothelial basement membrane. In that sense, Wang et al. 59 provided evidence for the MMP-9 induction by the KSHV-K1 protein, while Qian et al. 62 reported increased secretion of MMP-1, MMP-2 and MMP-9 in endothelial cells infected with KSHV and MMP-mediated invasion of these KSHV-infected endothelial cells. However, the critical role of these MMPs is only relevant in the invasion process into the newly colonized site, post extravasation.
In conclusion, angiogenesis, cell adhesion and communication likely contribute to the development of PEL and other KSHV-associated diseases and might represent potential therapeutic targets.
